Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael L Cheng

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Current Treatment Options in Oncology|January 10, 2014
Beyond sipuleucel-T: immune approaches to treating prostate cancerMichael L Cheng, Lawrence Fong
Urologic Oncology|February 24, 2018
Novel biomarkers in bladder cancerMichael L Cheng, Gopa Iyer
Frontiers in Oncology|January 17, 2014
Effects of RANKL-Targeted Therapy in Immunity and CancerMichael L Cheng, Lawrence Fong
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2018
Does TMB Impact the Effectiveness of TKIs in <i>EGFR</i>-Mutant NSCLC?Michael L Cheng, Geoffrey R Oxnard
Expert Opinion on Pharmacotherapy|December 4, 2012
Abiraterone acetate for the treatment of prostate cancerCharles J Ryan, Michael L Cheng
Clinical Science (London, England : 1979)|October 28, 2021
The immune niche of the liverMichael L Cheng, Diana Nakib, Catia T Perciani, et al.
Advances in Therapy|May 2, 2024
A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung CancerChristina Baik, Michael L Cheng, Martin Dietrich, et al.
Hemoglobin|October 2, 2014
Two new γ chain variants: Hb F-Augusta GA [(G)γ59(E3)Lys → Arg; HBG2: c.179A > G] and Hb F-Port Royal-II [(A)γ125(H3)Glu → Ala; HBG1: c.377A > C]Ferdane Kutlar, Afshin Ameri, Niren H Patel, et al.
CA: a Cancer Journal for Clinicians|November 9, 2020
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directionsMichael L Cheng, Eirini Pectasides, Glenn J Hanna, et al.
Melanoma Research|August 20, 2019
Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumabMichael A Postow, Scott D Chasalow, Deborah Kuk, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Current Treatment Options in Oncology|January 10, 2014
Beyond sipuleucel-T: immune approaches to treating prostate cancerMichael L Cheng, Lawrence Fong
Urologic Oncology|February 24, 2018
Novel biomarkers in bladder cancerMichael L Cheng, Gopa Iyer
Frontiers in Oncology|January 17, 2014
Effects of RANKL-Targeted Therapy in Immunity and CancerMichael L Cheng, Lawrence Fong
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 8, 2018
Does TMB Impact the Effectiveness of TKIs in <i>EGFR</i>-Mutant NSCLC?Michael L Cheng, Geoffrey R Oxnard
Expert Opinion on Pharmacotherapy|December 4, 2012
Abiraterone acetate for the treatment of prostate cancerCharles J Ryan, Michael L Cheng
Clinical Science (London, England : 1979)|October 28, 2021
The immune niche of the liverMichael L Cheng, Diana Nakib, Catia T Perciani, et al.
Advances in Therapy|May 2, 2024
A Practical Review of Encorafenib and Binimetinib Therapy Management in Patients with BRAF V600E-Mutant Metastatic Non-Small Cell Lung CancerChristina Baik, Michael L Cheng, Martin Dietrich, et al.
Hemoglobin|October 2, 2014
Two new γ chain variants: Hb F-Augusta GA [(G)γ59(E3)Lys → Arg; HBG2: c.179A > G] and Hb F-Port Royal-II [(A)γ125(H3)Glu → Ala; HBG1: c.377A > C]Ferdane Kutlar, Afshin Ameri, Niren H Patel, et al.
CA: a Cancer Journal for Clinicians|November 9, 2020
Circulating tumor DNA in advanced solid tumors: Clinical relevance and future directionsMichael L Cheng, Eirini Pectasides, Glenn J Hanna, et al.
Melanoma Research|August 20, 2019
Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumabMichael A Postow, Scott D Chasalow, Deborah Kuk, et al.
Pageof 4